<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yang J</submitter><funding>Beijing Municipal Education Commission</funding><pagination>170</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9824282</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Bifidobacterium, a common probiotic, is widely used in the food industry. Hyperglycemia in pregnancy has become a common disease that impairs the health of the mother and can lead to adverse pregnancy outcomes, such as preeclampsia, macrosomia, fetal hyperinsulinemia, and perinatal death. Currently, Bifidobacterium has been shown to have the potential to mitigate glycolipid derangements. Therefore, the use of Bifidobacterium-based probiotics to interfere with hyperglycemia in pregnancy may be a promising therapeutic option. We aimed to determine the potential effects of &lt;i>Bifidobacterium animalis&lt;/i> subsp. &lt;i>lactis&lt;/i> J-12 (J-12) in high-fat diet (HFD)/streptozotocin (STZ)-induced rats with hyperglycemia in pregnancy (HIP) and respective fetuses. We observed that J-12 or insulin alone </pubmed_abstract><journal>Nutrients</journal><pubmed_title>Ameliorative Effects of &lt;i>Bifidobacterium animalis&lt;/i> subsp. &lt;i>lactis&lt;/i> J-12 on Hyperglycemia in Pregnancy and Pregnancy Outcomes in a High-Fat-Diet/Streptozotocin-Induced Rat Model.</pubmed_title><pmcid>PMC9824282</pmcid><funding_grant_id>KM202010020002</funding_grant_id><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Xie Y</pubmed_authors><pubmed_authors>Li T</pubmed_authors><pubmed_authors>Ren J</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Ma Y</pubmed_authors><pubmed_authors>Pang Y</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>Jin J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ameliorative Effects of &lt;i>Bifidobacterium animalis&lt;/i> subsp. &lt;i>lactis&lt;/i> J-12 on Hyperglycemia in Pregnancy and Pregnancy Outcomes in a High-Fat-Diet/Streptozotocin-Induced Rat Model.</name><description>Bifidobacterium, a common probiotic, is widely used in the food industry. Hyperglycemia in pregnancy has become a common disease that impairs the health of the mother and can lead to adverse pregnancy outcomes, such as preeclampsia, macrosomia, fetal hyperinsulinemia, and perinatal death. Currently, Bifidobacterium has been shown to have the potential to mitigate glycolipid derangements. Therefore, the use of Bifidobacterium-based probiotics to interfere with hyperglycemia in pregnancy may be a promising therapeutic option. We aimed to determine the potential effects of &lt;i>Bifidobacterium animalis&lt;/i> subsp. &lt;i>lactis&lt;/i> J-12 (J-12) in high-fat diet (HFD)/streptozotocin (STZ)-induced rats with hyperglycemia in pregnancy (HIP) and respective fetuses. We observed that J-12 or insulin alone </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2026-04-08T11:32:26.356Z</modification><creation>2024-11-20T14:29:27.708Z</creation></dates><accession>S-EPMC9824282</accession><cross_references><pubmed>36615827</pubmed><doi>10.3390/nu15010170</doi></cross_references></HashMap>